ATOSSA THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant, a corporation organized and existing under the laws of the State of Delaware, has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the City of Seattle, State of Washington, on March 25, 2025.
| Atossa Therapeutics, Inc. | |
| By: | /s/ Steven C. Quay |
| Steven C. Quay, M.D., Ph.D. | |
| Chairman, President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Steven C. Quay and Heather Rees, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Office(s) | Date |
|---|---|---|
| /s/ Steven C. Quay | Chairman, President and Chief Executive Officer | March 25, 2025 |
| Steven C. Quay, M.D., Ph.D. | (Principal Executive Officer) | |
| /s/ Heather Rees | Chief Financial Officer | March 25, 2025 |
| Heather Rees | (Principal Financial and | |
| Accounting Officer) | ||
| /s/ Richard I. Steinhart | Director | March 25, 2025 |
| Richard I. Steinhart | ||
| /s/ Shu-Chih Chen | Director | March 25, 2025 |
| Shu-Chih Chen, Ph.D. | ||
| /s/ Jonathan Finn | Director | March 25, 2025 |
| Jonathan Finn | ||
| /s/ Stephen J. Galli | Director | March 25, 2025 |
| Stephen J. Galli, M.D. | ||
| /s/ H. Lawrence Remmel | Director | March 25, 2025 |
| H. Lawrence Remmel | ||
| /s/ Tessa Cigler | Director | March 25, 2025 |
| Tessa Cigler, M.D., M.P.H. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.